Last 12 months
Inside the activity.
0 purchase rows · 48 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 12 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 4 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 4 |
| Sep 2026 | 0 | 4 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2026 Filed Mar 4, 2026 23:45 UTC |
Gutwerg OriSVP, GENERICS
|
SaleCommon Stock | 2,060 | $76.50 | $157,590.00 |
DisclosureSEC source: 0001846478-26-000008 · wk-form4_1772667946.xml · nonDerivative · entry 1 Gutwerg Ori · CIK 0001846478 · SVP, GENERICS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,782 Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 23:46 UTC |
Mutz ChristopherHEAD OF RARE DISEASE
|
SaleCommon Stock | 417 | $74.00 | $30,858.00 |
DisclosureSEC source: 0001846487-26-000010 · wk-form4_1772668004.xml · nonDerivative · entry 1 Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,508 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025. Read SEC document |
| February 28, 2026 Filed Mar 2, 2026 22:59 UTC |
Rowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDS
|
Tax withholdingCommon Stock | 628 | $73.90 | $46,409.20 |
DisclosureSEC source: 0001507496-26-000007 · wk-form4_1772492369.xml · nonDerivative · entry 2 Rowland Thomas Andrew · CIK 0001507496 · SVP, HEAD - ESTABLISHED BRANDS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,502 F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 2,171 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| February 28, 2026 Filed Mar 2, 2026 22:59 UTC |
Mutz ChristopherHEAD OF RARE DISEASE
|
Tax withholdingCommon Stock | 2,221 | $73.90 | $164,131.90 |
DisclosureSEC source: 0001846487-26-000008 · wk-form4_1772492353.xml · nonDerivative · entry 2 Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,925 F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,342 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| February 28, 2026 Filed Mar 2, 2026 22:58 UTC |
Gutwerg OriSVP, GENERICS
|
Tax withholdingCommon Stock | 2,221 | $73.90 | $164,131.90 |
DisclosureSEC source: 0001846478-26-000006 · wk-form4_1772492317.xml · nonDerivative · entry 2 Gutwerg Ori · CIK 0001846478 · SVP, GENERICS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,842 F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,342 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| February 28, 2026 Filed Mar 2, 2026 22:58 UTC |
Lalwani NikhilDirector · PRESIDENT & CEO
|
Tax withholdingCommon Stock | 12,217 | $73.90 | $902,836.30 |
DisclosureSEC source: 0001822629-26-000006 · wk-form4_1772492331.xml · nonDerivative · entry 2 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 421,949 F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 23,883 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| February 28, 2026 Filed Mar 2, 2026 22:58 UTC |
Gassert ChadSVP - CORP. DEV. & STRATEGY
|
Tax withholdingCommon Stock | 2,221 | $73.90 | $164,131.90 |
DisclosureSEC source: 0001871002-26-000006 · wk-form4_1772492300.xml · nonDerivative · entry 2 Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,916 F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,342 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| February 28, 2026 Filed Mar 2, 2026 22:57 UTC |
Davis KristaSVP, CHIEF HR OFFICER
|
Tax withholdingCommon Stock | 1,555 | $73.90 | $114,914.50 |
DisclosureSEC source: 0001946439-26-000008 · wk-form4_1772492277.xml · nonDerivative · entry 2 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,518 F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,040 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| February 28, 2026 Filed Mar 2, 2026 22:57 UTC |
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
|
Tax withholdingCommon Stock | 1,555 | $73.90 | $114,914.50 |
DisclosureSEC source: 0001938861-26-000008 · wk-form4_1772492262.xml · nonDerivative · entry 2 Cook Meredith · CIK 0001938861 · SR. VP, GENERAL COUNSEL & SEC. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,890 F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,040 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| February 28, 2026 Filed Mar 2, 2026 22:57 UTC |
CAREY STEPHEN P.SVP & CFO
|
Tax withholdingCommon Stock | 2,773 | $73.90 | $204,924.70 |
DisclosureSEC source: 0001674236-26-000006 · wk-form4_1772492247.xml · nonDerivative · entry 2 CAREY STEPHEN P. · CIK 0001674236 · SVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,543 F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,079 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:59 UTC |
Shanmugam MuthusamyDirector · HEAD OF R&D, COO-NOVITIUM OPS
|
GrantCommon Stock | 11,116 | $77.15 | $857,599.40 |
DisclosureSEC source: 0001870913-26-000005 · wk-form4_1772492383.xml · nonDerivative · entry 1 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,056 F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:59 UTC |
Rowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDS
|
GrantCommon Stock | 6,021 | $77.15 | $464,520.15 |
DisclosureSEC source: 0001507496-26-000007 · wk-form4_1772492369.xml · nonDerivative · entry 1 Rowland Thomas Andrew · CIK 0001507496 · SVP, HEAD - ESTABLISHED BRANDS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,130 F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:59 UTC |
Mutz ChristopherHEAD OF RARE DISEASE
|
GrantCommon Stock | 21,306 | $77.15 | $1,643,757.90 |
DisclosureSEC source: 0001846487-26-000008 · wk-form4_1772492353.xml · nonDerivative · entry 1 Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,146 F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:58 UTC |
Gutwerg OriSVP, GENERICS
|
GrantCommon Stock | 12,969 | $77.15 | $1,000,558.35 |
DisclosureSEC source: 0001846478-26-000006 · wk-form4_1772492317.xml · nonDerivative · entry 1 Gutwerg Ori · CIK 0001846478 · SVP, GENERICS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,063 F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:58 UTC |
Lalwani NikhilDirector · PRESIDENT & CEO
|
GrantCommon Stock | 75,592 | $77.15 | $5,831,922.80 |
DisclosureSEC source: 0001822629-26-000006 · wk-form4_1772492331.xml · nonDerivative · entry 1 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 434,166 F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:58 UTC |
Gassert ChadSVP - CORP. DEV. & STRATEGY
|
GrantCommon Stock | 11,116 | $77.15 | $857,599.40 |
DisclosureSEC source: 0001871002-26-000006 · wk-form4_1772492300.xml · nonDerivative · entry 1 Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,137 F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:57 UTC |
Davis KristaSVP, CHIEF HR OFFICER
|
GrantCommon Stock | 10,810 | $77.15 | $833,991.50 |
DisclosureSEC source: 0001946439-26-000008 · wk-form4_1772492277.xml · nonDerivative · entry 1 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,073 F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:57 UTC |
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
|
GrantCommon Stock | 13,895 | $77.15 | $1,071,999.25 |
DisclosureSEC source: 0001938861-26-000008 · wk-form4_1772492262.xml · nonDerivative · entry 1 Cook Meredith · CIK 0001938861 · SR. VP, GENERAL COUNSEL & SEC. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,445 F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:57 UTC |
CAREY STEPHEN P.SVP & CFO
|
GrantCommon Stock | 22,233 | $77.15 | $1,715,275.95 |
DisclosureSEC source: 0001674236-26-000006 · wk-form4_1772492247.xml · nonDerivative · entry 1 CAREY STEPHEN P. · CIK 0001674236 · SVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,316 F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 22:31 UTC |
Mutz ChristopherHEAD OF RARE DISEASE
|
SaleCommon Stock | 5,323 | $78.02 | $415,300.46 |
DisclosureSEC source: 0001846487-26-000006 · wk-form4_1771885908.xml · nonDerivative · entry 1 Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,840 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025. F2 · price: The shares were sold in multiple trades at prices ranging from $77.20 to $78.58. The price reported above reflects the weighted average sales price. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 22:31 UTC |
Davis KristaSVP, CHIEF HR OFFICER
|
SaleCommon Stock | 1,730 | $77.99 | $134,922.70 |
DisclosureSEC source: 0001946439-26-000006 · wk-form4_1771885891.xml · nonDerivative · entry 2 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,263 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2025. F2 · price: The shares were sold in multiple trades at prices ranging from $77.45 to $78.58. The price reported above reflects the weighted average sales price. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 22:31 UTC |
Davis KristaSVP, CHIEF HR OFFICER
|
SaleCommon Stock | 2,084 | $77.53 | $161,572.52 |
DisclosureSEC source: 0001946439-26-000006 · wk-form4_1771885891.xml · nonDerivative · entry 1 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,993 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2025. Read SEC document |
| February 14, 2026 Filed Feb 17, 2026 21:08 UTC |
Rowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDS
|
Tax withholdingCommon Stock | 485 | $77.36 | $37,519.60 |
DisclosureSEC source: 0001507496-26-000005 · wk-form4_1771362529.xml · nonDerivative · entry 2 Rowland Thomas Andrew · CIK 0001507496 · SVP, HEAD - ESTABLISHED BRANDS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,109 F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 1,677 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| February 14, 2026 Filed Feb 17, 2026 21:08 UTC |
Mutz ChristopherHEAD OF RARE DISEASE
|
Tax withholdingCommon Stock | 2,403 | $77.36 | $185,896.08 |
DisclosureSEC source: 0001846487-26-000004 · wk-form4_1771362479.xml · nonDerivative · entry 3 Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,163 F4 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,697 shares of restricted stock, the grant of which was previously reported on February 16, 2024. Read SEC document |
| February 14, 2026 Filed Feb 17, 2026 21:07 UTC |
Lalwani NikhilDirector · PRESIDENT & CEO
|
Tax withholdingCommon Stock | 10,298 | $77.36 | $796,653.28 |
DisclosureSEC source: 0001822629-26-000004 · wk-form4_1771362436.xml · nonDerivative · entry 2 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 358,574 F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 20,132 shares of restricted stock, the grant of which was previously reported on February 16, 2024. Read SEC document |
| February 14, 2026 Filed Feb 17, 2026 21:05 UTC |
Gassert ChadSVP - CORP. DEV. & STRATEGY
|
Tax withholdingCommon Stock | 1,717 | $77.36 | $132,827.12 |
DisclosureSEC source: 0001871002-26-000004 · wk-form4_1771362348.xml · nonDerivative · entry 2 Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,021 F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,355 shares of restricted stock, the grant of which was previously reported on February 16, 2024. Read SEC document |
| February 14, 2026 Filed Feb 17, 2026 21:06 UTC |
Gutwerg OriSVP, GENERICS
|
Tax withholdingCommon Stock | 1,888 | $77.36 | $146,055.68 |
DisclosureSEC source: 0001846478-26-000004 · wk-form4_1771362392.xml · nonDerivative · entry 2 Gutwerg Ori · CIK 0001846478 · SVP, GENERICS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,094 F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,691 shares of restricted stock, the grant of which was previously reported on February 16, 2024. Read SEC document |
| February 14, 2026 Filed Feb 17, 2026 21:05 UTC |
Davis KristaSVP, CHIEF HR OFFICER
|
Tax withholdingCommon Stock | 1,290 | $77.36 | $99,794.40 |
DisclosureSEC source: 0001946439-26-000004 · wk-form4_1771362300.xml · nonDerivative · entry 2 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,077 F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,020 shares of restricted stock, the grant of which was previously reported on February 16, 2024. Read SEC document |
| February 14, 2026 Filed Feb 17, 2026 21:03 UTC |
CAREY STEPHEN P.SVP & CFO
|
Tax withholdingCommon Stock | 2,448 | $77.36 | $189,377.28 |
DisclosureSEC source: 0001674236-26-000004 · wk-form4_1771362205.xml · nonDerivative · entry 2 CAREY STEPHEN P. · CIK 0001674236 · SVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,083 F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 5,368 shares of restricted stock, the grant of which was previously reported on February 16, 2024. Read SEC document |
| February 14, 2026 Filed Feb 17, 2026 21:04 UTC |
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
|
Tax withholdingCommon Stock | 1,779 | $77.36 | $137,623.44 |
DisclosureSEC source: 0001938861-26-000006 · wk-form4_1771362255.xml · nonDerivative · entry 3 Cook Meredith · CIK 0001938861 · SR. VP, GENERAL COUNSEL & SEC. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,550 F3 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,691 shares of restricted stock, the grant of which was previously reported on February 16, 2024. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 21:04 UTC |
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
|
SaleCommon Stock | 500 | $76.80 | $38,400.00 |
DisclosureSEC source: 0001938861-26-000006 · wk-form4_1771362255.xml · nonDerivative · entry 2 Cook Meredith · CIK 0001938861 · SR. VP, GENERAL COUNSEL & SEC. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,329 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:08 UTC |
Rowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDS
|
Tax withholdingCommon Stock | 566 | $76.70 | $43,412.20 |
DisclosureSEC source: 0001507496-26-000005 · wk-form4_1771362529.xml · nonDerivative · entry 1 Rowland Thomas Andrew · CIK 0001507496 · SVP, HEAD - ESTABLISHED BRANDS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,594 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 1,958 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:08 UTC |
Mutz ChristopherHEAD OF RARE DISEASE
|
SaleCommon Stock | 7,032 | $76.55 | $538,299.60 |
DisclosureSEC source: 0001846487-26-000004 · wk-form4_1771362479.xml · nonDerivative · entry 2 Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,566 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025. F3 · price: The shares were sold in multiple trades at prices ranging from $75.43 to $76.92. The price reported above reflects the weighted average sales price. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:08 UTC |
Mutz ChristopherHEAD OF RARE DISEASE
|
Tax withholdingCommon Stock | 3,173 | $76.70 | $243,369.10 |
DisclosureSEC source: 0001846487-26-000004 · wk-form4_1771362479.xml · nonDerivative · entry 1 Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,598 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,202 shares of restricted stock, the grant of which was previously reported on February 18, 2025. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:07 UTC |
Lalwani NikhilDirector · PRESIDENT & CEO
|
Tax withholdingCommon Stock | 11,688 | $76.70 | $896,469.60 |
DisclosureSEC source: 0001822629-26-000004 · wk-form4_1771362436.xml · nonDerivative · entry 1 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 368,872 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 22,849 shares of restricted stock, the grant of which was previously reported on February 18, 2025. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:05 UTC |
Gassert ChadSVP - CORP. DEV. & STRATEGY
|
Tax withholdingCommon Stock | 1,608 | $76.70 | $123,333.60 |
DisclosureSEC source: 0001871002-26-000004 · wk-form4_1771362348.xml · nonDerivative · entry 1 Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,738 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,590 shares of restricted stock, the grant of which was previously reported on February 18, 2025. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:06 UTC |
Gutwerg OriSVP, GENERICS
|
Tax withholdingCommon Stock | 1,775 | $76.70 | $136,142.50 |
DisclosureSEC source: 0001846478-26-000004 · wk-form4_1771362392.xml · nonDerivative · entry 1 Gutwerg Ori · CIK 0001846478 · SVP, GENERICS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,982 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,917 shares of restricted stock, the grant of which was previously reported on February 18, 2025. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:05 UTC |
Davis KristaSVP, CHIEF HR OFFICER
|
Tax withholdingCommon Stock | 1,180 | $76.70 | $90,506.00 |
DisclosureSEC source: 0001946439-26-000004 · wk-form4_1771362300.xml · nonDerivative · entry 1 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,367 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,264 shares of restricted stock, the grant of which was previously reported on February 18, 2025. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:03 UTC |
CAREY STEPHEN P.SVP & CFO
|
Tax withholdingCommon Stock | 2,829 | $76.70 | $216,984.30 |
DisclosureSEC source: 0001674236-26-000004 · wk-form4_1771362205.xml · nonDerivative · entry 1 CAREY STEPHEN P. · CIK 0001674236 · SVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,531 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,202 shares of restricted stock, the grant of which was previously reported on February 18, 2025. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:04 UTC |
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
|
Tax withholdingCommon Stock | 1,534 | $76.70 | $117,657.80 |
DisclosureSEC source: 0001938861-26-000006 · wk-form4_1771362255.xml · nonDerivative · entry 1 Cook Meredith · CIK 0001938861 · SR. VP, GENERAL COUNSEL & SEC. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,829 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,243 shares of restricted stock, the grant of which was previously reported on February 18, 2025. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:13 UTC |
CAREY STEPHEN P.SVP & CFO
|
Tax withholdingCommon Stock | 5,503 | $76.25 | $419,603.75 |
DisclosureSEC source: 0001674236-26-000002 · wk-form4_1771017231.xml · nonDerivative · entry 1 CAREY STEPHEN P. · CIK 0001674236 · SVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,360 F1 · shares: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 16,210 performance stock units, the grant of which was previously reported on April 6, 2023. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:13 UTC |
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
|
Tax withholdingCommon Stock | 3,011 | $76.25 | $229,588.75 |
DisclosureSEC source: 0001938861-26-000004 · wk-form4_1771017195.xml · nonDerivative · entry 1 Cook Meredith · CIK 0001938861 · SR. VP, GENERAL COUNSEL & SEC. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,363 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 8,104 performance stock units, the grant of which was previously reported on April 6, 2023. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:12 UTC |
Gassert ChadSVP - CORP. DEV. & STRATEGY
|
Tax withholdingCommon Stock | 4,269 | $76.25 | $325,511.25 |
DisclosureSEC source: 0001871002-26-000002 · wk-form4_1771017125.xml · nonDerivative · entry 1 Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,346 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 11,578 performance stock units, the grant of which was previously reported on April 6, 2023. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:12 UTC |
Davis KristaSVP, CHIEF HR OFFICER
|
Tax withholdingCommon Stock | 3,017 | $76.25 | $230,046.25 |
DisclosureSEC source: 0001946439-26-000002 · wk-form4_1771017161.xml · nonDerivative · entry 1 Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,547 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 8,104 performance stock units, the grant of which was previously reported on April 6, 2023. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:11 UTC |
Gutwerg OriSVP, GENERICS
|
Tax withholdingCommon Stock | 4,267 | $76.25 | $325,358.75 |
DisclosureSEC source: 0001846478-26-000002 · wk-form4_1771017077.xml · nonDerivative · entry 1 Gutwerg Ori · CIK 0001846478 · SVP, GENERICS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,757 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 11,578 performance stock units, the grant of which was previously reported on April 6, 2023. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:09 UTC |
Lalwani NikhilDirector · PRESIDENT & CEO
|
Tax withholdingCommon Stock | 30,659 | $76.25 | $2,337,748.75 |
DisclosureSEC source: 0001822629-26-000002 · wk-form4_1771016985.xml · nonDerivative · entry 1 Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 380,560 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 63,686 performance stock units, the grant of which was previously reported on April 6, 2023. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:08 UTC |
Mutz ChristopherHEAD OF RARE DISEASE
|
Tax withholdingCommon Stock | 4,546 | $76.25 | $346,632.50 |
DisclosureSEC source: 0001846487-26-000002 · wk-form4_1771016933.xml · nonDerivative · entry 1 Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,771 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 11,578 performance stock units, the grant of which was previously reported on April 6, 2023. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:07 UTC |
Rowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDS
|
Tax withholdingCommon Stock | 1,762 | $76.25 | $134,352.50 |
DisclosureSEC source: 0001507496-26-000003 · wk-form4_1771016868.xml · nonDerivative · entry 1 Rowland Thomas Andrew · CIK 0001507496 · SVP, HEAD - ESTABLISHED BRANDS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,160 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 5,788 performance stock units, the grant of which was previously reported. F2 · balance_after: Includes 128 shares of ANI Pharmaceuticals, Inc. Common Stock that were acquired under the ANI Pharmaceuticals, Inc. Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:06 UTC |
Shanmugam MuthusamyDirector · HEAD OF R&D, COO-NOVITIUM OPS
|
Tax withholdingCommon Stock | 2,898 | $76.25 | $220,972.50 |
DisclosureSEC source: 0001870913-26-000002 · wk-form4_1771016786.xml · nonDerivative · entry 1 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,940 F1 · shares: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 11,578 performance stock units, the grant of which was previously reported on April 6, 2023. F2 · balance_after: Includes 250 shares of ANI Pharmaceuticals, Inc. Common Stock that were acquired under the ANI Pharmaceuticals, Inc. Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 13, 2026 Filed Jan 14, 2026 23:14 UTC |
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
|
SaleCommon Stock | 500 | $84.33 | $42,165.00 |
DisclosureSEC source: 0001938861-26-000002 · wk-form4_1768432456.xml · nonDerivative · entry 1 Cook Meredith · CIK 0001938861 · SR. VP, GENERAL COUNSEL & SEC. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,374 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.